A carregar...

Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges

MDM2 is a primary cellular inhibitor of p53. It inhibits p53 function by multiple mechanisms, each of which, however, is mediated by their direct interaction. It has been proposed that small-molecule inhibitors designed to block the MDM2–p53 interaction may be effective in the treatment of human can...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cold Spring Harb Perspect Med
Main Authors: Wang, Shaomeng, Zhao, Yujun, Aguilar, Angelo, Bernard, Denzil, Yang, Chao-Yie
Formato: Artigo
Idioma:Inglês
Publicado em: Cold Spring Harbor Laboratory Press 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5411684/
https://ncbi.nlm.nih.gov/pubmed/28270530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/cshperspect.a026245
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!